Cabozantinib in Advanced Salivary Gland Cancer Patients

NCT03729297 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped safety issues

Conditions

Salivary Gland Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Radboud University Medical Center

Collaborators

[object Object]